Jeffrey D. Helterbrand

Author

Also Known As

J Helterbrand, J. Helterbrand, J.D. Helterbrand, Jeffrey D Helterbrand, Jeffrey D. Helterbrand, Jeffrey Donald Helterbrand, Jeffrey Helterbrand

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Vanderbilt University Université Paris Cité Iowa State University Cliniques Universitaires Saint-Luc

About

Jeffrey D. Helterbrand is an author at Eli Lilly (United States) specializing in medicine, image segmentation, and medical image computing.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	736
2	Engineering	3	3	80
3	Natural Sciences	2	2	37
4	Anatomy	1	1	43
5	Computer Engineering	1	1	16

Jeffrey D. Helterbrand

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis Gordon R. Bernard, Jean‐Louis Vincent, Pierre‐François Laterre, New England Journal of Medicine	2001	6.1K
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus, Critical Care Medicine	2003	282
Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis S. Betty Yan, Jeffrey D. Helterbrand, Daniel Hartman, CHEST Journal InflammationSevere SepsisPoor OutcomeDisease PathophysiologyInflammatory Marker	2001	257
The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000) GR Bernard, SP LaRosa, Pierre‐François Laterre, Digital Access to Libraries InflammationTranslational MedicineSevere SepsisProtein CImmunology	2001	213
Design and methods of the Raloxifene Use for The Heart (RUTH) study Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger, The American Journal of Cardiology Heart FailureRaloxifene UseCardiovascular DiseaseMedicinePharmacotherapy	2001	166
Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis William L. Macias, Jean-François Dhainaut, Sau Chi Betty Yan, Clinical Pharmacology & Therapeutics	2002	98
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group A Stone, William D. Bushnell, Jon Denne, European Journal of Cancer OncologyCancer ManagementClinical TrialsOutcomes ResearchCancer Registration	2011	57
Universal cokriging under intrinsic coregionalization Jeffrey D. Helterbrand, Noel Cressie Mathematical Geology Modulation (Music)Intrinsic CoregionalizationSpirituality	1994	48
Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei Steven P. LaRosa, Steven M. Opal, Barbara G. Utterback, International Journal of Infectious Diseases	2005	44
Application of automatic image segmentation to tibiae and vertebrae from ovariectomized rats Jeffrey D. Helterbrand, Richard E. Higgs, Philip W. Iversen, Bone Imaging AnatomyImage AnalysisEngineeringMedical ImagingBone Imaging	1997	43

Page 1